1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A dopaminergic neurotoxic compound which produces irreversible clinical, chemical, and pathological alterations that mimic those found in Parkinson disease.
| Descriptor ID |
D015632
|
| MeSH Number(s) |
D03.383.725.450
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine".
Below are MeSH descriptors whose meaning is more specific than "1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine".
This graph shows the total number of publications written about "1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine" by people in this website by year, and whether "1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 1 | 1 |
| 2001 | 0 | 1 | 1 |
| 2002 | 0 | 3 | 3 |
| 2003 | 0 | 1 | 1 |
| 2004 | 1 | 1 | 2 |
| 2005 | 4 | 1 | 5 |
| 2006 | 1 | 0 | 1 |
| 2007 | 0 | 2 | 2 |
| 2008 | 0 | 1 | 1 |
| 2009 | 0 | 2 | 2 |
| 2010 | 2 | 0 | 2 |
| 2012 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine" by people in Profiles.
-
Pattarini R, Rong Y, Shepherd KR, Jiao Y, Qu C, Smeyne RJ, Morgan JI. Long-lasting transcriptional refractoriness triggered by a single exposure to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrimidine. Neuroscience. 2012 Jul 12; 214:84-105.
-
Phani S, Gonye G, Iacovitti L. VTA neurons show a potentially protective transcriptional response to MPTP. Brain Res. 2010 Jul 9; 1343:1-13.
-
Gerecke KM, Jiao Y, Pani A, Pagala V, Smeyne RJ. Exercise protects against MPTP-induced neurotoxicity in mice. Brain Res. 2010 Jun 23; 1341:72-83.
-
Zigmond MJ, Cameron JL, Leak RK, Mirnics K, Russell VA, Smeyne RJ, Smith AD. Triggering endogenous neuroprotective processes through exercise in models of dopamine deficiency. Parkinsonism Relat Disord. 2009 Dec; 15 Suppl 3:S42-5.
-
Chen PC, Vargas MR, Pani AK, Smeyne RJ, Johnson DA, Kan YW, Johnson JA. Nrf2-mediated neuroprotection in the MPTP mouse model of Parkinson's disease: Critical role for the astrocyte. Proc Natl Acad Sci U S A. 2009 Feb 24; 106(8):2933-8.
-
Arias RL, Sung ML, Vasylyev D, Zhang MY, Albinson K, Kubek K, Kagan N, Beyer C, Lin Q, Dwyer JM, Zaleska MM, Bowlby MR, Dunlop J, Monaghan M. Amiloride is neuroprotective in an MPTP model of Parkinson's disease. Neurobiol Dis. 2008 Sep; 31(3):334-41.
-
Boyd JD, Jang H, Shepherd KR, Faherty C, Slack S, Jiao Y, Smeyne RJ. Response to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) differs in mouse strains and reveals a divergence in JNK signaling and COX-2 induction prior to loss of neurons in the substantia nigra pars compacta. Brain Res. 2007 Oct 17; 1175:107-16.
-
Pattarini R, Smeyne RJ, Morgan JI. Temporal mRNA profiles of inflammatory mediators in the murine 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrimidine model of Parkinson's disease. Neuroscience. 2007 Mar 16; 145(2):654-68.
-
Anderson DW, Bradbury KA, Schneider JS. Neuroprotection in Parkinson models varies with toxin administration protocol. Eur J Neurosci. 2006 Dec; 24(11):3174-82.
-
Lloyd SA, Faherty CJ, Smeyne RJ. Adult and in utero exposure to cocaine alters sensitivity to the Parkinsonian toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Neuroscience. 2006 Feb; 137(3):905-13.